

Your reference
Our reference
Date

October 4, 2024

Changes to Franklin Templeton Investment Funds (“FTIF”) and the Underlying Funds (as defined below)

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

Zurich International Life Limited
(a company incorporated in the Isle of Man with limited liability)

25-26/F, One Island East
18 Westlands Road
Island East, Hong Kong

Website: www.zurich.com.hk

Zurich International Life Limited provides life assurance, investment and protection products and is authorized by the Isle of Man Financial Services Authority.

Registered in the Isle of Man number 20126C.

Registered office: Zurich House,
Isle of Man Business Park,
Douglas, Isle of Man, IM2 2QZ,
British Isles

We accept full responsibility for the accuracy of the content of this document. Unless otherwise specified herein, capitalized terms used in this letter shall have the meanings assigned to such terms in the Explanatory Memorandum of FTIF dated April 2024, as amended from time to time (the “Explanatory Memorandum”).

Dear valued customer,

We are writing to let you know about the changes to FTIF and the Underlying Funds. You have invested in at least one of the investment choices corresponding to the Underlying Funds, which are listed in the “Which investment choices are affected?” table below under the column “Name and code of the investment choice”.

Which investment choices are affected?

Name and code of the investment choice (Individually, the “Investment Choice”; collectively, the “Investment Choices”)	Name of the corresponding underlying fund (Individually, the “Underlying Fund”; collectively, the “Underlying Funds”)	Applicable scheme (Collectively, the “Schemes”)
Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund (Code: USDTC)	Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund	<ul style="list-style-type: none"> International Wealth Account IWA Pacific
Franklin Templeton Investment Funds - Franklin India Fund (Code: FWUSD)	Franklin Templeton Investment Funds - Franklin India Fund	
Franklin Templeton Investment Funds - Franklin U.S. Government Fund (Code: ZVUSD)	Franklin Templeton Investment Funds - Franklin U.S. Government Fund	
Franklin Templeton Investment Funds - Templeton Asian Growth Fund USD (Code: KOUSD)	Franklin Templeton Investment Funds - Templeton Asian Growth Fund	

What is happening?

We have been notified by Franklin Templeton Investments (Asia) Limited, as the Hong Kong Representative of FTIF, of the changes set out below. Unless otherwise stated, the changes set out below took effect as of July 19, 2024 (the “Effective Date”).

I. Reduction of Annual Management Charges (“AMC”)

With effect from October 1, 2024, the annual management charges of the Franklin U.S. Government Fund shall be reduced as follows:

Share Class	Current AMC	Reduced AMC
Class A	0.95%	0.70%

II. Removal of the transitional provisions from the investment policy of the Franklin U.S. Government Fund in relation to TBA transactions

Following their entry into force on May 27, 2024, the investment policy of the Franklin U.S. Government Fund shall be updated to remove the transitional provisions from the investment policy in relation to TBA transactions. In this connection, (i) the wording “with effect from May 27, 2024” under the second paragraph of the investment policy of the Underlying Fund and (ii) the footnote numbered 18 which specifies that the Underlying Fund will be subject to “TBA Transaction risk” with effect from May 27, 2024 shall be removed.

III. Updated SFDR pre-contractual disclosures of certain Underlying Funds

The SFDR pre-contractual disclosures of certain Underlying Funds shall be updated to reflect the following key changes:

- (a) Introduction of a minimum proportion of sustainable investments of 10% for Franklin Biotechnology Discovery Fund

Franklin Biotechnology Discovery Fund’s sustainable investments include a minimum allocation of 1% of the portfolio to sustainable investments with an environmental objective and a minimum allocation of 1% of the portfolio to sustainable investments with a social objective.

Franklin Biotechnology Discovery Fund’s stock selection criteria are based on the Investment Manager’s fundamental bottom-up research with growth, quality, and valuation analysis at its core. It simultaneously assesses target issuers for positive ESG characteristics, aiming to allocate at least 10% of Franklin Biotechnology Discovery Fund’s portfolio to sustainable investments as defined by the Investment Manager as investments in companies that: (i) derive at least 25% of their revenues from products and services that address at least one of the 17 United Nations Sustainable Development Goals (UN SDG)’s (source: MSCI), or (ii) gain and maintain Science Based Target Initiative (SBTi) approved carbon emission reduction targets and thus are considered to be contributing to fighting against climate change. In addition, the target company would be considered a sustainable investment if it meets the criteria of the Do No Significant Harm (DNSH) and Good Governance tests, both of which are assessed using data from MSCI.

For the avoidance of doubt, Franklin Biotechnology Discovery Fund is not classified as ESG funds, pursuant to the “Circular to management companies of SFC authorized unit trusts and mutual funds - ESG funds” issued by the SFC on June 29, 2021.

- (b) Updates to reflect that “The data is reviewed on a quarterly basis and includes each company’s scope 1+2 greenhouse gas emissions.” under the “Does this financial product consider principal adverse impacts on sustainability factors?” section in the SFDR pre-contractual disclosures of the following Underlying Funds:
- Franklin India Fund
 - Templeton Asian Growth Fund

Please refer to the updated SFDR pre-contractual disclosures of the relevant Underlying Funds for details.

They are available for download from the Hong Kong Representative's website at https://franklintempletonprod.widen.net/s/jqdp5bk5xt/ftif-sfdr-pre-contractual-disclosure-annexes_hk_en¹ (English version) and https://franklintempletonprod.widen.net/s/hv85nxn6tb/ftif-sfdr-pre-contractual-disclosure-annexes_hk_cn¹ (traditional Chinese version).

IV. Other updates

The Explanatory Memorandum shall also be updated to reflect the below:

- (a) Updates to the information relating to the conducting officers of the Management Company.
- (b) Updates to reflect that the Franklin NextStep Moderate Fund is no longer offered exclusively to the selected intermediaries by invitation but can be distributed more widely.
- (c) The heading and the paragraph under the sub-section headed "VALUATION DAY" under the section headed "PURCHASE AND REDEMPTION OF SHARES" shall be deleted for clarification purposes as the revised definition of "Valuation Day" (effective from January 1, 2024) is set out in the relevant Underlying Fund's profile.
- (d) Other administrative, clarificatory and/or editorial updates.

As confirmed by the Hong Kong Representative of FTIF, the changes set out above do not amount to a material change to the Underlying Funds. There is no material change or increase in the overall risk profiles of any of the Underlying Funds following the above changes. Further, the above changes do not have a material adverse impact on Investors' rights or interests (including changes that may limit Investors' ability in exercising their rights), and the above changes are not expected to give rise to any change in the fee level or fee structure of any of the Underlying Funds.

Any costs and/or expenses incurred in connection with the above changes shall be borne by the Management Company, other than the cost of publishing the letter to notify Investors of the above changes, which is estimated to be approximately HKD 120,000 and which shall be charged and allocated to the Underlying Funds based on the pro rata share of the Net Asset Value of the relevant funds.

The Explanatory Memorandum of FTIF and Product Key Facts Statements of the Underlying Funds shall be updated to reflect the above changes in due course. An updated version of the Explanatory Memorandum and Product Key Facts Statements shall be available for download from the Hong Kong Representative of FTIF's website at www.franklintempleton.com.hk¹ in due course.

What does this mean to you?

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 3405 7150 or email us at helppoint.hk@hk.zurich.com and we will be happy to help.

Yours faithfully,

Zurich International Life Limited
(a company incorporated in the Isle of Man with limited liability)

¹ The website has not been reviewed by the Securities and Futures Commission.



Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.

¹ The website has not been reviewed by the Securities and Futures Commission.



ZURICH
蘇黎世

有關富蘭克林鄧普頓投資基金（「FTIF」）及該等相關基金（定義見下文）之變更

蘇黎世國際人壽保險有限公司
（於人島註冊成立之有限公司）

香港港島東華蘭路18號
港島東中心25-26樓

網址：www.zurich.com.hk

蘇黎世國際人壽保險有限公司是人島
Financial Services Authority所認可，
提供人壽保險、投資及保障產品。

於人島的註冊號碼為20126C。

註冊辦事處：Zurich House,
Isle of Man Business Park,
Douglas, Isle of Man, IM2 2QZ,
British Isles

此乃重要函件，務請您即時垂注。您如對本函件的内容有任何疑問，請尋求專業意見。

我們就此函件所轉載資料的準確性承擔全部責任。除非另有訂明，否則本函件所載詞彙應與
FTIF日期為2024年4月的基金說明書（經不時修訂）（「基金說明書」）所載者具有相同涵義。

親愛的客戶：

我們謹此致函通知您有關FTIF及該等相關基金的變更。您已投資於該等相關基金相應的至少一個投資選擇，其列於下表「受影響的投資選擇」中「投資選擇的名稱及代碼」一欄。

受影響的投資選擇

投資選擇（各稱為「該投資選擇」，統稱為「該等投資選擇」）的名稱及代碼	相應的相關基金（各稱為「該相關基金」，統稱為「該等相關基金」）名稱	適用計劃（統稱「計劃」）
富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金 （代碼：USDTC）	富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金	<ul style="list-style-type: none"> 國際創富計劃 景緻人生 翱翔人生
富蘭克林鄧普頓投資基金 - 富蘭克林印度基金 （代碼：FWUSD）	富蘭克林鄧普頓投資基金 - 富蘭克林印度基金	
富蘭克林鄧普頓投資基金 - 富蘭克林美國政府基金 （代碼：ZVUSD）	富蘭克林鄧普頓投資基金 - 富蘭克林美國政府基金	
富蘭克林鄧普頓投資基金 - 鄧普頓亞洲增長基金（美元） （代碼：KOUSD）	富蘭克林鄧普頓投資基金 - 鄧普頓亞洲增長基金	

修訂事項

FTIF的香港代表富蘭克林鄧普頓投資（亞洲）有限公司已通知我們以下變更。除非另有說明，以下變更自2024年7月19日（「生效日期」）起生效。

I. 每年管理費（「每年管理費」）下調

自2024年10月1日起，富蘭克林美國政府基金的每年管理費應下調如下：

股份類別	現行每年管理費	經下調的每年管理費
A類股份	0.95%	0.70%

II. 刪除富蘭克林美國政府基金的投資政策中與TBA交易有關的過渡性條文

在2024年5月27日生效後，富蘭克林美國政府基金的投資政策應作出更新，以刪除投資政策中與TBA交易有關的過渡性條文。就此，該相關基金的投資政策的第二段內「由2024年5月27日起」的措詞及(ii)訂明由2024年5月27日起，該相關基金將面臨「TBA交易風險」的第18號腳註應予刪除。

III. 更新若干該等相關基金的SFDR合約前披露

若干該等相關基金的SFDR合約前披露應作出更新，以反映以下重要變更：

(a) 富蘭克林生物科技新領域基金引入10%的最低可持續投資比例

富蘭克林生物科技新領域基金的可持續投資包括將其投資組合的至少1%分配予具有環境目標的可持續投資，及將其投資組合的至少1%分配予具有社會目標的可持續投資。

富蘭克林生物科技新領域基金的選股標準是基於投資經理自下而上的基本面研究，以增長、質素及估值分析為核心。其同時評估目標發行人的正面ESG特徵，旨在將富蘭克林生物科技新領域基金投資組合的至少10%分配予投資經理定義的可持續投資，即對以下公司的投資：(i)至少25%的收入來自至少實現17個聯合國可持續發展目標之一的產品和服務（資料來源：MSCI），或(ii)獲得並維持科學碳目標倡議(SBTi)批准的碳減排目標，從而被認為有助於應對氣候變化。此外，如果目標公司符合不造成重大損害(DNSH)及良好管治測試的標準，則將被視為可持續投資，這兩項測試均使用MSCI的數據進行評估。

為免存疑，根據證監會2021年6月29日發出的《致證監會認可單位信託及互惠基金的管理公司的通函 - 環境、社會及管治基金》，富蘭克林生物科技新領域基金將不會被歸類為ESG基金。

- (b) 反映下列該等相關基金的SFDR合約前披露中「此金融產品是否考慮了對可持續性因素的主要不利影響？」一節下的「數據每季度檢討一次，包括各公司的範圍1+2的溫室氣體排放量」的更新：
- 富蘭克林印度基金
 - 鄧普頓亞洲增長基金

請參閱該等相關基金經更新的SFDR合約前披露，以了解詳情。

其可於香港代表的網站下載https://franklintempletonprod.widen.net/s/jqdp5bk5xt/ftif-sfdr-pre-contractual-disclosure-annexes_hk_en¹（英文版本）及https://franklintempletonprod.widen.net/s/hv85nrxn6tb/ftif-sfdr-pre-contractual-disclosure-annexes_hk_cn¹（繁體中文版本）。

IV. 其他更新

基金說明書亦應作出更新，以反映以下變更：

- (a) 有關管理公司的營運總監的資料更新。
- (b) 有關反映富蘭克林領步均衡基金不再專門透過邀請向選定的中介機構提供，而是可更廣泛分銷的更新。
- (c) 為清楚起見，應刪除「認購及贖回單位」一節中「估值日」一分節下的標題及段落，因為「估值日」的經修訂定義（自2024年1月1日起生效）已載於該相關基金的概況中。
- (d) 其他行政、澄清及 / 或編輯更新。

FTIF的香港代表已確認，以上所載之變更並不構成對該等相關基金的重大變更。上述變更之後，任何該等相關基金的整體風險概況並無重大變化或上升。此外，上述變更不會對投資者的權利或利益產生重大不利影響（包括可能限制投資者行使其權利的變更），且上述變更預計不會導致任何該等相關基金的收費水平或收費結構發生任何變化。

與上述變更相關的任何費用及 / 或開支應由管理公司承擔（刊發信件以通知投資者上述變更的費用除外，該費用預計約為120,000港元，應由該等相關基金按相關基金股份的資產淨值比例承擔）。

FTIF的基金說明書及該等相關基金的产品資料概要將適時更新，以反映上述變更。基金說明書及產品資料概要的更新版本可適時於FTIF的香港代表網站www.franklintempleton.com.hk¹下載。

對您產生的影響

如您在考慮上述變更後仍希望繼續投資於該等投資選擇，則無需就此修訂作出任何行動。倘若您不欲繼續投資於該等投資選擇，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選擇的指示，費用全免。

我們建議您首先諮詢您的持牌保險中介人，以取得其他投資選擇的建議。有關本公司投資選擇（包括費用及收費，以及其相關風險因素）的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

如您對本函件或投資選擇中的投資有任何疑問，請聯絡您的持牌保險中介人。您亦可致電+852 3405 7150或電郵至helppoint.hk@hk.zurich.com聯絡客戶服務部，我們將樂意為您效勞。

¹本網站未經證券及期貨事務監察委員會審核。



蘇黎世國際人壽保險有限公司
(於人島註冊成立之有限公司)
2024年10月4日

註：投資涉及風險，您的投資價值及收益可因市場及貨幣波動而下跌，有可能導致您不能取回所有投資款項。